ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

[1]  S. Solomon,et al.  GUIDELINES AND STANDARDS , 2010 .

[2]  O. Alfieri,et al.  [Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)]. , 2013, Giornale italiano di cardiologia.

[3]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[4]  Shunichi Homma,et al.  Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.

[5]  P. Sanders,et al.  Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. , 2012, Journal of the American College of Cardiology.

[6]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[7]  S. Werns.  Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .

[8]  Otto Kamp,et al.  EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. , 2012, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[9]  Arno W. Hoes,et al.  The Diagnostic Value of Physical Examination and Additional Testing in Primary Care Patients With Suspected Heart Failure , 2011, Circulation.

[10]  Mike Kirby,et al.  Guidelines on the management of cardiovascular diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology ( ESC ) , 2011 .

[11]  E. Nagel,et al.  Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry. , 2011, JACC. Cardiovascular imaging.

[12]  Harlan M Krumholz,et al.  National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. , 2011, JAMA.

[13]  M. Borggrefe,et al.  Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure , 2011, Circulation.

[14]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[15]  W. Levy,et al.  Establishing prognosis in heart failure: a multimarker approach. , 2011, Progress in cardiovascular diseases.

[16]  A. Hoes,et al.  Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. , 2011, Journal of cardiac failure.

[17]  J. Cleland,et al.  Which components of heart failure programmes are effective? A systematic review and meta‐analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review , 2011, European journal of heart failure.

[18]  J. Rogers,et al.  Patient selection for left ventricular assist devices. , 2011, Congestive heart failure.

[19]  N. Lakkis,et al.  Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study. , 2011, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[20]  Ajay M Shah,et al.  In search of new therapeutic targets and strategies for heart failure: recent advances in basic science , 2011, The Lancet.

[21]  Stefan D Anker,et al.  Telemedicine and remote management of patients with heart failure , 2011, The Lancet.

[22]  Theresa McDonagh,et al.  UK guidelines for referral and assessment of adults for heart transplantation , 2011, Heart.

[23]  J. Madias.  Why Recording of an Electrocardiogram Should be Required in Every Inpatient and Outpatient Encounter of Patients with Heart Failure , 2011, Pacing and clinical electrophysiology : PACE.

[24]  Michael J Ackerman,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[25]  G. Beller,et al.  SPECT Imaging for Detecting Coronary Artery Disease and Determining Prognosis by Noninvasive Assessment of Myocardial Perfusion and Myocardial Viability , 2011, Journal of cardiovascular translational research.

[26]  W. Ghali,et al.  Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. , 2011, Heart rhythm.

[27]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[28]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[29]  R. McKelvie,et al.  The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. , 2011, The Canadian journal of cardiology.

[30]  R. Arena,et al.  Cardiopulmonary exercise testing is a core assessment for patients with heart failure. , 2011, Congestive heart failure.

[31]  F. Rutten,et al.  Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests , 2011, European journal of heart failure.

[32]  T. Edvardsen,et al.  Echocardiographic Evaluation of Hemodynamics in Patients With Decompensated Systolic Heart Failure , 2011, Circulation. Cardiovascular imaging.

[33]  Diederick E Grobbee,et al.  Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis , 2011, Heart.

[34]  Adrian V. Hernández,et al.  Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[35]  Gerasimos S Filippatos,et al.  Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation , 2011, European journal of heart failure.

[36]  R. Wachter,et al.  Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial , 2011, European journal of heart failure.

[37]  A. Arai,et al.  Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance , 2011, European heart journal.

[38]  Adrian F Hernandez,et al.  Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[39]  W. Paulus,et al.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.

[40]  A. Strömberg,et al.  European Society of Cardiology Heart Failure Association Standards for delivering heart failure care , 2011, European journal of heart failure.

[41]  Keyur B Shah,et al.  Implantable Mechanical Circulatory Support: Demystifying Patients With Ventricular Assist Devices and Artificial Hearts , 2011, Clinical cardiology.

[42]  B. Chow,et al.  Recent advances in cardiac imaging for patients with heart failure. , 2011, Current opinion in cardiology.

[43]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[44]  Anna Strömberg,et al.  Self‐care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[45]  H. Riess,et al.  Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. , 2011, American heart journal.

[46]  T Douglas Bradley,et al.  Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. , 2011, Journal of the American College of Cardiology.

[47]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[48]  R. Vasan,et al.  Epidemiology and clinical course of heart failure with preserved ejection fraction , 2011, European journal of heart failure.

[49]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[50]  Henry Krum,et al.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study , 2011, European journal of heart failure.

[51]  M. Gheorghiade,et al.  Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) , 2011, European journal of heart failure.

[52]  Munir Pirmohamed,et al.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[53]  D. DeMets,et al.  Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) , 2011, Circulation. Heart failure.

[54]  Finn Gustafsson,et al.  2010 Focused Update of ESC Guidelines on Device Therapy in Heart Failure , 2011 .

[55]  M. Cheitlin.  Ultrafiltration is Associated With Fewer Rehospitalizations than Continuous Diuretic Infusion in Patients With Decompensated Heart Failure: Results From UNLOAD , 2011 .

[56]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[57]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[58]  Helmut Baumgartner,et al.  ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). , 2010, European heart journal.

[59]  G. Steinbeck,et al.  OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction , 2010, Circulation.

[60]  J. McMurray,et al.  Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial , 2010, Heart.

[61]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[62]  Inger Ekman,et al.  Population Impact of Heart Failure and the Most Common Forms of Cancer: A Study of 1 162 309 Hospital Cases in Sweden (1988 to 2004) , 2010, Circulation. Cardiovascular quality and outcomes.

[63]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[64]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[65]  Elizabeth Avery,et al.  Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial. , 2010, JAMA.

[66]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[67]  Christopher M O'Connor,et al.  Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. , 2010, Journal of the American College of Cardiology.

[68]  K. Sliwa,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy , 2010, European journal of heart failure.

[69]  M. Chung,et al.  Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. , 2010, Journal of the American College of Cardiology.

[70]  Sumit R. Majumdar,et al.  Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database , 2010, Diabetes Care.

[71]  P. Ponikowski,et al.  Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.

[72]  L. Lund,et al.  Patient selection for left ventricular assist devices , 2010, European journal of heart failure.

[73]  J. Zamorano,et al.  European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). , 2010, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[74]  E. Schmid,et al.  Introduction and epidemiology , 2018, ESC CardioMed.

[75]  Stefan D Anker,et al.  Systolic heart failure. , 2010, The New England journal of medicine.

[76]  M. Laakso,et al.  Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[77]  Otto Kamp,et al.  Lenient versus strict rate control in patients with atrial fibrillation. , 2010, The New England journal of medicine.

[78]  D. Leong,et al.  eart Failure With Normal Ejection Fraction : he Complementary Roles of Echocardiography nd CMR Imaging arryl , 2022 .

[79]  Jeroen J. Bax,et al.  Recent developments in heart failure imaging. , 2010, JACC. Cardiovascular imaging.

[80]  J. McMurray,et al.  Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction , 2010, Heart.

[81]  B. Billah,et al.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.

[82]  Akshay S. Desai,et al.  Patient expectations from implantable defibrillators to prevent death in heart failure. , 2010, Journal of cardiac failure.

[83]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[84]  Markolf Hanefeld,et al.  Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial , 2010, European heart journal.

[85]  J. McMurray,et al.  Clinical practice. Systolic heart failure. , 2010, The New England journal of medicine.

[86]  Juerg Schwitter,et al.  Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology , 2010, European heart journal.

[87]  Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative , 2009, European heart journal.

[88]  S. Werns.  A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? , 2010 .

[89]  J. Zamorano,et al.  European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). , 2010, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[90]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[91]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[92]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[93]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[94]  U. Siebert,et al.  Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. , 2009, The New England journal of medicine.

[95]  A. Habets,et al.  Defibrillator implantation early after myocardial infarction. , 2009, The New England journal of medicine.

[96]  Arturo Evangelista,et al.  European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. , 2009, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[97]  T. Therneau,et al.  Hospitalizations after heart failure diagnosis a community perspective. , 2009, Journal of the American College of Cardiology.

[98]  G. Jondeau,et al.  B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. , 2009, European heart journal.

[99]  Jeroen J. Bax,et al.  The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy. , 2009, Journal of the American College of Cardiology.

[100]  Scott Lim,et al.  Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. , 2009, Journal of the American College of Cardiology.

[101]  S. Solomon,et al.  Albuminuria in chronic heart failure: prevalence and prognostic importance , 2009, The Lancet.

[102]  S. Solomon,et al.  Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial , 2009, European journal of heart failure.

[103]  Nader Moazami,et al.  Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. , 2009, Journal of the American College of Cardiology.

[104]  O. Simonetti,et al.  The CMR examination in heart failure. , 2009, Heart failure clinics.

[105]  S. Myerson.  Valvular and hemodynamic assessment with CMR. , 2009, Heart failure clinics.

[106]  P Barton,et al.  Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. , 2009, Health technology assessment.

[107]  P. Ponikowski,et al.  Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology , 2009, European journal of heart failure.

[108]  Christopher M O'Connor,et al.  Coronary bypass surgery with or without surgical ventricular reconstruction. , 2009, The New England journal of medicine.

[109]  W. Kraus,et al.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.

[110]  A. Wardley,et al.  Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring , 2009, British Journal of Cancer.

[111]  John G F Cleland,et al.  Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide , 2009, European journal of heart failure.

[112]  Colin Simpson,et al.  Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003: A Population Study of 5.1 Million People , 2009, Circulation.

[113]  J. McMurray,et al.  Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology , 2009, European journal of heart failure.

[114]  M. Pfeffer,et al.  Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program , 2009, European journal of heart failure.

[115]  F. Flachskampf,et al.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography. , 2008, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[116]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[117]  Harlan M Krumholz,et al.  What works in chronic care management: the case of heart failure. , 2009, Health affairs.

[118]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[119]  Stefano Ghio,et al.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. , 2008, Journal of the American College of Cardiology.

[120]  N. Paul,et al.  Perioperative β-Blockers : Use With Caution Perioperative β Blockers in Patients Having Non-Cardiac Surgery : A Meta-Analysis , 2010 .

[121]  David O. Martin,et al.  Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. , 2008, The New England journal of medicine.

[122]  Y. Sheikine,et al.  Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure , 2008, Current heart failure reports.

[123]  Gissi-Hf Investigators.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[124]  Gianni Tognoni,et al.  Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). , 2008, Journal of the American College of Cardiology.

[125]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[126]  W Frank Peacock,et al.  State of the art: Using natriuretic peptide levels in clinical practice , 2008, European journal of heart failure.

[127]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[128]  J. Nicholl,et al.  Noninvasive ventilation in acute cardiogenic pulmonary edema. , 2008, The New England journal of medicine.

[129]  J. Schwitter.  Extending the frontiers of cardiac magnetic resonance. , 2008, Circulation.

[130]  Jose Luis Zamorano,et al.  Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). , 2008, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[131]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[132]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[133]  Joanne Brown,et al.  Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. , 2008, Journal of the American College of Cardiology.

[134]  Jeroen J. Bax,et al.  Results of the Predictors of Response to CRT (PROSPECT) Trial , 2008, Circulation.

[135]  B. Ewald,et al.  Meta‐analysis of B type natriuretic peptide and N‐terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction , 2008, Internal medicine journal.

[136]  F. Sarullo,et al.  Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? , 2008, Clinical science.

[137]  P. Tchou,et al.  Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. , 2007, The New England journal of medicine.

[138]  André Lamy,et al.  F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). , 2007, Journal of the American College of Cardiology.

[139]  Renu Virmani,et al.  A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology , 2022 .

[140]  A. Skene,et al.  Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease , 2007, Diabetes Care.

[141]  J. Daubert,et al.  Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. , 2007, European heart journal.

[142]  K. Dickstein,et al.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[143]  A. Hoes,et al.  Clinical epidemiology of heart failure , 2007, Heart.

[144]  J. Kirkpatrick,et al.  Echocardiography in heart failure: applications, utility, and new horizons. , 2007, Journal of the American College of Cardiology.

[145]  M. Pfeffer,et al.  Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. , 2007, Journal of the American College of Cardiology.

[146]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[147]  E. Fisher,et al.  Should aspirin be continued in patients started on warfarin? , 2004, Journal of General Internal Medicine.

[148]  E. Fleck,et al.  How we perform myocardial perfusion with cardiovascular magnetic resonance. , 2007, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[149]  Magdi H Yacoub,et al.  Left ventricular assist device and drug therapy for the reversal of heart failure. , 2006, The New England journal of medicine.

[150]  C. Huerta,et al.  Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population , 2006, Heart.

[151]  Stuart Russell,et al.  Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[152]  C. Fonseca.  Diagnosis of heart failure in primary care , 2006, Heart Failure Reviews.

[153]  Alan S Maisel,et al.  How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. , 2006, American heart journal.

[154]  A. Hungin,et al.  The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. , 2006, The British journal of general practice : the journal of the Royal College of General Practitioners.

[155]  William Stewart,et al.  Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[156]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[157]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[158]  J. Ornato,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidel , 2006, European heart journal.

[159]  Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. , 2006, BMJ.

[160]  S. Anker,et al.  Cachexia in chronic heart failure: Prognostic implications and novel therapeutic approaches , 2005, Current heart failure reports.

[161]  Vic Hasselblad,et al.  Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. , 2005, JAMA.

[162]  P. Hildebrandt,et al.  Combination Therapy with Metolazone and Loop Diuretics in Outpatients with Refractory Heart Failure: An Observational Study and Review of the Literature , 2005, Cardiovascular Drugs and Therapy.

[163]  P. Poole‐Wilson,et al.  Exercise Intolerance in Adult Congenital Heart Disease: Comparative Severity, Correlates, and Prognostic Implication , 2005, Circulation.

[164]  R. McKelvie,et al.  Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice , 2005, European journal of heart failure.

[165]  K. Swedberg,et al.  Exploring symptoms in chronic heart failure , 2005, European journal of heart failure.

[166]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[167]  M. Cowie,et al.  The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study , 2005, European journal of heart failure.

[168]  P. Hildebrandt,et al.  Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. , 2005, Journal of cardiac failure.

[169]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[170]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[171]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[172]  Shu-lin Wu,et al.  Prophylactic Use of an Implantable Cardioverter-defibrillator after Acute Myocardial Infarction , 2005 .

[173]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[174]  Eva Pietrzak,et al.  A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. , 2004, Archives of internal medicine.

[175]  K. Khunti,et al.  Accuracy of a 12‐lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta‐analysis , 2004, European journal of heart failure.

[176]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[177]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[178]  G. Guyatt,et al.  Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. , 2004, Journal of cardiac failure.

[179]  Haya R Rubin,et al.  Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. , 2004, JAMA.

[180]  K. Swedberg,et al.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. , 2004, Journal of the American College of Cardiology.

[181]  N. Christensen,et al.  Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability , 2004, Scandinavian journal of clinical and laboratory investigation.

[182]  E. Retyk,et al.  Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). , 2004, Current opinion in cardiology.

[183]  J. Cleland,et al.  Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? , 2003, Journal of the American College of Cardiology.

[184]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[185]  E. Topol,et al.  Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. , 2003, JAMA.

[186]  M. Pfeffer,et al.  Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.

[187]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[188]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[189]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[190]  J. Rouleau,et al.  Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. , 2003, American heart journal.

[191]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[192]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[193]  A. Turpie,et al.  Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[194]  C. Witt,et al.  Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. , 2003, American heart journal.

[195]  J. Rouleau,et al.  Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. , 2003, JAMA.

[196]  N. Hollenberg,et al.  Literature alert , 2002 .

[197]  J. Daubert,et al.  Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. , 2002, European heart journal.

[198]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[199]  J. Cohn,et al.  Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. , 2002, Journal of the American College of Cardiology.

[200]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[201]  P. Vandervoort,et al.  Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. , 2002, Journal of the American College of Cardiology.

[202]  Simon Capewell,et al.  The current cost of heart failure to the National Health Service in the UK , 2002, European journal of heart failure.

[203]  R. F. Kelly,et al.  Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. , 2002, The American journal of medicine.

[204]  W. Cherng,et al.  EFFECT OF VERAPAMIL IN ELDERLY PATIENTS WITH LEFT VENTRICULAR DIASTOLIC DYSFUNCTION AS A CAUSE OF CONGESTIVE HEART FAILURE , 2002, International journal of clinical practice.

[205]  M. Cuffe.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. , 2002, JAMA.

[206]  A. DeMaria,et al.  Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. , 2002, The American journal of medicine.

[207]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[208]  S Capewell,et al.  More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.

[209]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[210]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[211]  K. Bailey,et al.  Clinical criteria and biochemical markers for the detection of systolic dysfunction. , 2000, Journal of cardiac failure.

[212]  R. Cappato,et al.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). , 2000, Circulation.

[213]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[214]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[215]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[216]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[217]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[218]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[219]  ICHAEL,et al.  THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE , 2000 .

[220]  S Shepperd,et al.  Discharge planning from hospital to home. , 2000, The Cochrane database of systematic reviews.

[221]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[222]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[223]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[224]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[225]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[226]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[227]  P. Ponikowski,et al.  Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. , 1998, International journal of cardiology.

[228]  V. Somers,et al.  Dopamine depresses minute ventilation in patients with heart failure. , 1998, Circulation.

[229]  Y. Moshkovitz,et al.  Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema , 1998, The Lancet.

[230]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[231]  M. Janse,et al.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials , 1997, The Lancet.

[232]  M. Quiñones,et al.  Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. , 1997, Journal of the American College of Cardiology.

[233]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[234]  J. Cohn,et al.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. , 1997, Circulation.

[235]  H. Figulla,et al.  Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. , 1997, Journal of cardiac failure.

[236]  G R Sutherland,et al.  Assessing diagnosis in heart failure: which features are any use? , 1997, QJM : monthly journal of the Association of Physicians.

[237]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[238]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.

[239]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[240]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[241]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[242]  J. McMurray,et al.  Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction , 1996, BMJ.

[243]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[244]  S. Yusuf,et al.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.

[245]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[246]  Fibrinolytic Therapy Trialists' Collaborative Group.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994, The Lancet.

[247]  K. Channer,et al.  Combination diuretic treatment in severe heart failure: a randomised controlled trial. , 1994, British heart journal.

[248]  B. Massie,et al.  Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. , 1993, Journal of the American College of Cardiology.

[249]  Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. , 1993, Journal of the American College of Cardiology.

[250]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[251]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[252]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[253]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[254]  S. Nattel,et al.  Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. , 1991, Circulation.

[255]  H. Black,et al.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. , 1990, The American journal of cardiology.

[256]  J. Hampton,et al.  Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study. , 1989, International journal of cardiology.

[257]  J. McMurray,et al.  Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. , 1989, Journal of cardiovascular pharmacology.

[258]  L. Tan,et al.  DETRIMENTAL HAEMODYNAMIC EFFECTS OF CYCLIZINE IN HEART FAILURE , 1988, The Lancet.

[259]  T. Moreland,et al.  A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. , 1988, European heart journal.

[260]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[261]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.

[262]  B. Brent,et al.  Coronary artery bypass surgery in patients with left ventricular dysfunction. , 1986, The American journal of medicine.

[263]  P. Poole‐Wilson,et al.  Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. , 1985, British medical journal.

[264]  F. Tristani,et al.  Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. , 1982, The New England journal of medicine.